Burkitt Lymphoma: Relapsed/Refractory

Home » Understanding Lymphoma » About Lymphoma and Subtypes » Non-Hodgkin Lymphoma » Burkitt Lymphoma » Burkitt Lymphoma: Relapsed/Refractory

Burkitt Lymphoma

Home » Understanding Lymphoma » About Lymphoma and Subtypes » Non-Hodgkin Lymphoma » Burkitt Lymphoma » Burkitt Lymphoma: Relapsed/Refractory

Relapsed/Refractory

The term “relapsed” refers to disease that reappears or grows again after a period of remission.

The term “refractory” is used to describe when the lymphoma does not respond to treatment (meaning that the cancer cells continue to grow) or when the response to treatment does not last very long.

Central Nervous System (CNS) involvement at diagnosis of Burkitt lymphoma is recognized as the strongest risk factor for relapse; therefore, recommended treatment regimens include treatment to protect the CNS, which may be given intrathecally (injected into the spinal fluid).

To learn more about primary central nervous system (CNS) lymphoma, visit the CNS Lymphoma page.

Learn More

To learn more about burkitt lymphoma, download the Burkitt Lymphoma Fact Sheet. Want to talk to someone? For answers to lymphoma-related questions 
and resources, contact our Helpline at (800) 500-9976 or helpline@lymphoma.org.

Additional Resources

To learn more about burkitt lymphoma, download the Burkitt Lymphoma Fact Sheet.

Events

Events Search and Views Navigation

Event Views Navigation

Today

  • Lymphoma Talk: Minneapolis

    Minneapolis Marriott City Center 30 South 7th Street, Minneapolis, Minnesota

    Lymphoma Talk is a two-hour weekday evening in-person program led by lymphoma experts that provides information about lymphoma in three breakout sessions.

  • Living with Lymphoma

    Virtual Event

    Living with Lymphoma provides the latest information about lymphoma diagnosis, current treatment options, and patient support issues.

  • What Care Partners Should Know Webinar

    Virtual Event

    Webinars are hour-long interactive programs discussing the diagnosis and treatment of specific lymphoma subtypes and key research and treatment updates. Webinars feature a presentation from the featured expert, with the remainder of the time allocated to an extensive Q&A session. Program Overview: